

## Publications

**Glypican-1 as a target for fluorescence molecular imaging of bladder cancer**, Polikarpov DM, Campbell DH, Zaslavsky AB, Lund ME, Wu A, Lu Y, Palapattu GS, Walsh BJ, Zvyagin AV, Gillatt DA. Int J Urol. 2021 Sep 8. doi: [10.1111/iju.14683](https://doi.org/10.1111/iju.14683). Epub ahead of print

**Safety and tolerability of Miltuximab® - a first in human study in patients with advanced solid cancers**, Dhanusha Sabanathan, Douglas H. Campbell, Vicki M. Velonas, Sandra Wissmueller, Hubert Mazure, Marko Trifunovic, Pirooz Poursoltan, Kevin Ho Shon, Tiffany R. Mackay, Maria E. Lund, Yanling Lu, Paul J. Roach, Dale L. Bailey, Bradley J. Walsh, David Gillatt, Howard Gurney. Asia Oceania Journal of Nuclear Medicine and Biology 2021; 9(2):86-100 <https://dx.doi.org/10.22038/aojnmb.2021.55600.1386>

**Radioimmunotherapy for Solid Tumors – Spotlight on Glypican-1 as a Radioimmunotherapy Target**, Dhanusha Sabanathan, Maria E Lund, Douglas H Campbell, Bradley J Walsh, Howard Gurney. Accepted in Therapeutic Advances in Medical Oncology.

**Glypican-1 as a Target for Fluorescence Molecular Imaging of Bladder Cancer**, Dmitry M. Polikarpov, Douglas H. Campbell, Alexander B. Zaslavsky, Maria E. Lund, Angela Wu, Yanling Lu, Ganesh S. Palapattu, Bradley J. Walsh, Andrei V. Zvyagin, David A. Gillatt. Under review at International Journal of Urology

**A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells**, Maria E. Lund, Christopher B. Howard, Kristofer J. Thurecht, Douglas H. Campbell, Stephen M. Mahler, Bradley J. Walsh. BMC Cancer. 2020, 20: 1-13 doi: [10.1186/s12885-020-07562-1](https://doi.org/10.1186/s12885-020-07562-1)

**RetroSPECT: Gallium-67 as a Long-Lived Imaging Agent for Theranostics**, Dale L. Bailey, Dhanusha Sabanathan, Alireza Aslani, Douglas H. Campbell, Bradley J. Walsh, Nigel A. Lengkeek. Asia Ocean J Nucl Med Biol. 2021, 9(1): 1-8. doi: [10.22038/AOJNMB.2020.51714.1355](https://doi.org/10.22038/AOJNMB.2020.51714.1355)

**The feasibility of Miltuximab®-IRDye700DX-mediated photoimmunotherapy of solid tumors**, Dmitry M. Polikarpov, Douglas H. Campbell, Maria E. Lund, Yanling Lu, Yiqing Lu, Jiehua Wu, Bradley J. Walsh, Andrei V. Zvyagin, David A. Gillatt. Photodiagnosis and Photodynamic Therapy 2020, 15:102064 <https://doi.org/10.1016/j.pdpdt.2020.102064>

**Near-Infrared Molecular Imaging of Glioblastoma by Miltuximab®-IRDye800CW as a Potential Tool for Fluorescence-Guided Surgery**, Dmitry M. Polikarpov, Douglas H. Campbell, Lucinda S. McRobb, Jiehua Wu, Maria E. Lund, Yanling Lu, Sergey M. Deyev, Andrew S. Davidson, Bradley J. Walsh, Andrei V. Zvyagin and David A. Gillatt. Cancers 2020, 12(4): 984; [http://doi.org/10.3390/cancers12040984](https://doi.org/10.3390/cancers12040984)

**Targeted beta therapy of prostate cancer with <sup>177</sup>Lu-labelled Miltuximab® antibody against glypican-1 (GPC-1)**, Mei-Chun Yeh, Brian W. C. Tse, Nicholas L. Fletcher, Zachary H. Houston, Maria E. Lund, Marianna Volpert, Chelsea Stewart, Kamil A. Sokolowski, Varinder Jeet, Kristofer J. Thurecht, Douglas H. Campbell, Bradley J. Walsh, Colleen C. Nelson and Pamela J. Russell. EJNMMI Research 2020, 10(1):46; <https://doi.org/10.1186/s13550-020-00637-x>

**The Role of Glypican-1 in the Tumour Microenvironment**, Maria E. Lund, Douglas H. Campbell and Bradley J. Walsh. Advances in Experimental Medicine and Biology 2020, 1245: 163-176; [https://doi.org/10.1007/978-3-030-40146-7\\_8](https://doi.org/10.1007/978-3-030-40146-7_8)

**Functionalized Upconversion Nanoparticles for Targeted Labelling of Bladder Cancer Cells**, Dmitry M. Polikarpov, Luen Liang, Andrew Care, Anwar Sunna, Douglas H. Campbell, Bradley J. Walsh, Irina Balalaeva, Andrei V. Zvyagin, David A. Gillatt and Evgenii Guryev. Biomolecules 2019, 9(12): 820; <https://doi.org/10.3390/biom9120820>

**Development of a reliable assay to measure glypican-1 in plasma and serum reveals circulating glypican-1 as a novel prostate cancer biomarker**, Rachel A. Levin, Maria E. Lund, Quach Truong, Angela Wu, Neal D. Shore, Daniel R. Saltzstein, Raoul S. Concepcion, Thomas A. Paivanas, Arletta van Breda, Jennifer Beebe-Dimmer, Julie J. Ruterbusch, Sandra Wissmueller, Douglas H. Campbell and Bradley J. Walsh. *Oncotarget* 2018, 9(32): 22359–22367; <https://doi.org/10.18632/oncotarget.25009>

**Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer**, Douglas H. Campbell, Maria E. Lund, Aline L. Nocon, Paul J. Cozzi, Mark Frydenberg, Paul De Souza, Belinda Schiller, Jennifer L. Beebe-Dimmer, Julie J. Ruterbusch, Bradley J. Walsh. *PLoS ONE* 2018, 13(4): e0196017; <https://doi.org/10.1371/journal.pone.0196017>

**Glypican-1 as a Biomarker for Prostate Cancer: Isolation and Characterization**, Quach Truong, Irene O. Justiniano, Aline L. Nocon, Julie T. Soon, Sandra Wissmueller, Douglas H. Campbell and Bradley J. Walsh. *J Cancer* 2016, 7(8): 1002-1009; <https://doi.org/10.7150/jca.14645>